Economic consequences of investing in anti-HCV antiviral treatment from the Italian NHS perspective : a real-world-based analysis of PITER data

Marcellusi, Andrea, Viti, Raffaella, Kondili, Loreta A., Rosato, Stefano, Vella, Stefano and Mennini, Francesco Saverio (2018) Economic consequences of investing in anti-HCV antiviral treatment from the Italian NHS perspective : a real-world-based analysis of PITER data. PharmacoEconomics, ISSN (print) 1170-7690 (Epub Ahead of Print)

Full text available as:
[img] Text
Marcellusi-A-42273-AAM.pdf - Accepted Version
Restricted to Repository staff only until 30 October 2019.

Download (510kB)

Abstract

OBJECTIVE: We estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C virus (HCV) treatment access policies in Italy. METHODS: A multistate, 20-year time horizon Markov model of HCV liver disease progression was developed. Fibrosis stage, age and genotype distributions were derived from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. The treatment efficacy, disease progression probabilities and direct costs in each health state were obtained from the literature. The break-even point in time (BPT) was defined as the period of time required for the cumulative costs saved to recover the Italian NHS investment in DAA treatment. Three different PITER enrolment periods, which covered the full DAA access evolution in Italy, were considered. RESULTS: The disease stages of 2657 patients who consecutively underwent DAA therapy from January 2015 to December 2017 at 30 PITER clinical centres were standardized for 1000 patients. The investment in DAAs was considered to equal €25 million, €15 million, and €9 million in 2015, 2016, and 2017, respectively. For patients treated in 2015, the BPT was not achieved, because of the disease severity of the treated patients and high DAA prices. For 2016 and 2017, the estimated BPTs were 6.6 and 6.2 years, respectively. The total cost savings after 20 years were €50.13 and €55.50 million for 1000 patients treated in 2016 and 2017, respectively. CONCLUSIONS: This study may be a useful tool for public decision makers to understand how HCV clinical and epidemiological profiles influence the economic burden of HCV.

Item Type: Article
Additional Information: This work was supported by PITER [grant number Research Project PITER2010 RF-2010-2315839]
Research Area: Health services research
Faculty, School or Research Centre: Kingston Business School > Department of Accountancy, Finance and Informatics
Related URLs:
Depositing User: Andrea Marcellusi
Date Deposited: 07 Nov 2018 08:09
Last Modified: 10 Jan 2019 16:05
DOI: https://doi.org/10.1007/s40273-018-0733-3
URI: http://eprints.kingston.ac.uk/id/eprint/42273

Actions (Repository Editors)

Item Control Page Item Control Page